- ISIN
- US98419J2069
- CUSIP
- 98419J206
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 5, 1989
Highlights
- Market Cap
- $731.51M
- Enterprise Value
- $787.05M
- EPS (TTM)
- $1.76
- PE Ratio
- 23.80
- PEG Ratio
- 1.06
- Total Revenue (TTM)
- $48.56M
- Gross Profit (TTM)
- $45.24M
- EBITDA (TTM)
- $7.50M
- Year Range
- $22.29 - $42.81
- Target Price
- $53.75
- ROA (TTM)
- 11.59%
- ROE (TTM)
- 33.93%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XOMA Performance Chart
XOMA Corporation (XOMA) is up 58.0% since the beginning of the year. At $42 per share, XOMA is trading just below its 52-week high of $43. Investors who bought $1,000 worth of XOMA shares 5 years ago would now be looking at an investment worth $1,313.
Loading charts...
Returns By Period
XOMA Corporation (XOMA) has returned 57.95% so far this year and 74.64% over the past 12 months. Looking at the last ten years, XOMA has achieved an annualized return of 14.93%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
XOMA Corporation
- 1D
- 0.26%
- 1M
- 0.84%
- YTD
- 57.95%
- 6M
- 64.19%
- 1Y
- 74.64%
- 3Y*
- 31.41%
- 5Y*
- 5.60%
- 10Y*
- 14.93%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
XOMA Monthly Returns History
Based on dividend-adjusted daily data since Apr 5, 1989, XOMA's average daily return is +0.09%, while the average monthly return is +1.42%. At this rate, an investment would double in approximately 4.1 years.
Historically, 48% of months were positive and 52% were negative. The best month was Dec 2010 with a return of +115.6%, while the worst month was Jul 2015 at -81.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.
On a daily basis, XOMA closed higher 44% of trading days. The best single day was Dec 22, 2010 with a return of +88.3%, while the worst single day was Jul 22, 2015 at -77.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.50% | -0.51% | 22.88% | 30.51% | 1.88% | 0.70% | 57.95% | ||||||
| 2025 | 1.26% | -14.69% | -12.20% | 20.62% | 3.00% | 1.78% | -1.27% | 30.51% | 18.69% | -14.43% | -2.58% | -17.24% | 1.18% |
| 2024 | 7.95% | 21.73% | -1.07% | 5.36% | 1.78% | -8.14% | 12.96% | 9.30% | -9.47% | 14.05% | 10.76% | -21.43% | 42.05% |
| 2023 | 10.27% | 4.88% | -0.80% | -12.88% | -7.56% | 11.12% | -16.62% | -10.98% | 0.50% | 33.78% | -21.27% | 24.66% | 0.54% |
| 2022 | -0.62% | 5.84% | 27.59% | -31.27% | -5.30% | 22.35% | 5.48% | -15.40% | -9.91% | -7.54% | 27.84% | -13.08% | -11.75% |
| 2021 | -17.92% | -0.06% | 12.73% | -6.74% | -22.57% | 15.37% | -4.71% | -3.95% | -20.47% | 1.01% | -17.96% | 1.66% | -52.75% |
Benchmark Metrics
XOMA Corporation has an annualized alpha of 10.65%, beta of 1.17, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since April 05, 1989.
- This stock participated in 187.59% of S&P 500 Index downside but only 111.93% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.65%
- Beta
- 1.17
- R²
- 0.06
- Upside Capture
- 111.93%
- Downside Capture
- 187.59%
Return for Risk
Risk / Return Rank
XOMA ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for XOMA Corporation (XOMA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XOMA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.64 | ||
| Sortino ratioReturn per unit of downside risk | -0.89 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.37 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 1.77 | 2.78 | -1.01 |
| Martin ratioReturn relative to average drawdown | 3.79 | 12.44 | -8.65 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the XOMA Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the XOMA Corporation was 99.96%, occurring on Feb 10, 2017. The portfolio has not yet recovered.
The current XOMA Corporation drawdown is 99.56%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2017 bear market2017 | -99.96%Feb 2017 | 25y 11mo | — | 35y 3moMar 1991 - now |
1990 bear market1990 | -40.38%Sep 1990 | 8mo 22d | 4mo 23d | 1y 1moJan 1990 - Feb 1991 |
1989 correction1989 | -17.20%Sep 1989 | 16d | 3mo 5d | 3mo 21dSep 1989 - Jan 1990 |
1989 correction1989 | -12.82%Jun 1989 | 10d | 2mo 2d | 2mo 12dJun 1989 - Aug 1989 |
1989 pullback1989 | -6.15%Apr 1989 | 4d | 1d | 5dApr 1989 - Apr 1989 |
Drawdown Indicators
| XOMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -56.78% | -43.18% |
Max Drawdown (1Y)Largest decline over 1 year | -42.37% | -9.10% | -33.27% |
Max Drawdown (3Y)Largest decline over 3 years | -44.63% | -18.90% | -25.73% |
Max Drawdown (5Y)Largest decline over 5 years | -63.32% | -25.43% | -37.89% |
Max Drawdown (10Y)Largest decline over 10 years | -70.71% | -33.92% | -36.79% |
Current DrawdownCurrent decline from peak | -99.56% | -1.80% | -97.76% |
Average DrawdownAverage peak-to-trough decline | -86.25% | -10.71% | -75.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.78% | 2.03% | +17.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of XOMA Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how XOMA Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for XOMA, comparing it with other companies in the Biotechnology industry. Currently, XOMA has a P/E ratio of 23.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for XOMA compared to other companies in the Biotechnology industry. XOMA currently has a PEG ratio of 1.1. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XOMA relative to other companies in the Biotechnology industry. Currently, XOMA has a P/S ratio of 15.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XOMA in comparison with other companies in the Biotechnology industry. Currently, XOMA has a P/B value of 8.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XOMA
Add XOMA Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XOMA